A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AB102 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Medical Director
- Phone Number: +1-510-462-3330
- Email: ClinicalTrialInquiry@arcusbio.com
Study Locations
-
-
-
Groningen, Netherlands
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol.
- BMI: 19.0 to 30.0 kg/m2, inclusive, at screening.
- All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.
- Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG, vital signs, and complete neurological examination, as judged by the Investigator.
- Participants must follow protocol-specified contraception guidance.
Exclusion Criteria:
- Have a history of relevant atopy, drug hypersensitivity and/or food allergies.
- Using tobacco products within 3 months prior to the screening.
- Have a significant infection or known inflammatory process on screening or admission.
- Have received any vaccination within 14 days of admission date for non-live vaccines or 28 days of admission date for live attenuated vaccines.
- History of alcohol abuse or drug addiction in the last 2 years (including soft drugs like cannabis products).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SAD Part
Escalating single oral doses of AB102 will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Experimental: SAD Part Placebo
Escalating single oral doses of placebo will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Placebo Comparator: MAD Part
Escalating multiple oral doses of AB102 will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Placebo Comparator: MAD Part Placebo
Escalating multiple oral doses of placebo will be given to participants
|
Administered orally as specified in the treatment arm
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants experiencing Adverse Events (AEs)
Time Frame: Up to 49 days
|
Up to 49 days
|
|
Maximum observed plasma concentration (Cmax) for SAD and MAD Parts
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Time to attain maximum observed plasma concentration (tmax) for SAD and MAD Parts
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Terminal elimination half-life (t1/2) for SAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to last sample (AUClast) for SAD and MAD Parts
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24h) for SAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for SAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) for MAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Accumulation ratio (Racc(Cmax))for MAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Accumulation ratio(Racc(AUCtau)) for MAD Part
Time Frame: Up to 28 days
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Arcus Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- ARC-102-101
- 2026-526279-52-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.